News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–59
Matches
59
Sources here
13
Companies here
1
Search results Stored financial headlines

Active search

59 matching headlines

Ticker or company: LEGNMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Market source Market update Main company 🇺🇸 United States

Legend Biotech (LEGN) Replaces CEO Ying Huang With Interim Chief Alan Bash

Legend Biotech (LEGN) has announced that CEO Ying Huang has stepped down and Alan Bash has been appointed as Interim CEO. Bash previously led the CARVYKTI business unit, Legend Biotech's only approved cell therapy, which analysts consider central to the company's investment case. This …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

A webcast will carry Legend Biotech's Q2 results review Aug. 11

Legend Biotech (NASDAQ: LEGN) will host an investor conference call and live audio webcast on August 11, 2026, at 8:00 a.m. ET to discuss its second-quarter 2026 financial results. Senior management will present an overview of the company's financial performance, with a replay and …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results

Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, will host an investor conference call on Tuesday, August 11, 2026, at 8:00 a.m. ET to discuss its second-quarter 2026 financial results. Senior management will provide an overview of the quarterly financial performance …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Analyst action Main company 🇺🇸 United States

Raymond James cuts Legend Biotech stock price target on CEO departure

Raymond James has lowered its price target for Legend Biotech Corp. (NASDAQ:LEGN) from $86 to $58, while maintaining an Outperform rating, following the departure of CEO Ying Huang. Alan Bash has been appointed interim CEO. Despite the leadership change and increased competition in the …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Bamboo Works Earnings Main company 🇺🇸 United States

Legend Bio CEO resigns, shares tumble

Legend Biotech Corp. (LEGN.US) announced the resignation of CEO Huang Ying, causing its shares to tumble 13.3% and wipe out all 2026 gains. Alan Bash will serve as interim CEO while a search for a permanent replacement is underway. Despite a 56% revenue increase …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

LEGN Stock Plunges 15% After Sudden CEO Exit — But Analyst Reiterates Optimism In Company’s Under-Development Lymphoma Asset

Legend Biotech (LEGN) stock plunged 15% following the sudden resignation of its CEO, Ying Huang, who stepped down on July 24. Despite this setback, RBC Capital reiterated an 'Outperform' rating on the stock, though lowering its price target to $59 from $63, citing optimism …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Market update Main company 🇺🇸 United States

Legend Biotech's In Vivo CAR-T Cell Therapy Data Validates Approach, RBC Capital Markets Says

RBC Capital Markets has indicated that Legend Biotech's in vivo CAR-T cell therapy data validates the company's approach. This suggests promising developments in Legend Biotech's therapeutic strategies, particularly in the innovative field of CAR-T cell treatments. The market reaction to this validation from RBC …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
StocksToTrade Analyst action Main company 🇺🇸 United States

LEGN Stock Slumps As UBS Slashes Price Target On Carvykti Concerns

Legend Biotech Corporation (LEGN) stock has dropped significantly following a UBS downgrade from Buy to Neutral and a price target cut from $49 to $28. This change in sentiment is primarily due to concerns over weaker-than-expected growth for their lead cell therapy, Carvykti, and …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Legend Biotech (LEGN) CEO Ying Huang exits as board appoints interim chief

Legend Biotech Corporation announced that CEO Ying Huang resigned from his position and the board, effective July 24, 2026, though he will continue as an advisor through August for a smooth transition. His resignation is not attributed to any disagreements regarding the company's operations …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quiver Quantitative Market update Main company 🇺🇸 United States

Legend Biotech Announces CEO Transition, Appoints Alan Bash Interim Chief Executive Officer

Legend Biotech announced that CEO Ying Huang, Ph.D., has stepped down, effective July 24, 2026, but will remain as an advisor through August to ensure a smooth transition. Alan Bash, President of the CARVYKTI Business Unit, has been appointed Interim CEO as the Board …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Fierce Pharma Market update Main company 🇺🇸 United States

Legend Biotech CEO abruptly steps down without permanent replacement

Legend Biotech's CEO, Ying Huang, Ph.D., has resigned, with Alan Bash appointed as interim CEO while a permanent successor is sought. Huang's departure is stated to be amicable, contrasting with past leadership issues at the company. This leadership change comes as Legend Biotech faces …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

LEGN|Legend Biotech Corp|Price:22.220|Chg%:-1.310

This article provides a detailed company profile for Legend Biotech Corp (LEGN), a global biopharmaceutical company focusing on cell therapies for oncology. It outlines the company's lead product candidate, cilta-cel, and its pipeline, along with key company information, executive details, and institutional shareholding data.

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Legend Biotech CEO Ying Huang Steps Down; Search Begins

Legend Biotech (NASDAQ: LEGN) announced that CEO Ying Huang has stepped down, effective July 24, 2026, but will remain an advisor through August for a smooth transition. Alan Bash, President of the CARVYKTI Business Unit, has been appointed Interim CEO, and the company has …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Legend Biotech Corp (LEGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Legend Biotech Corp (LEGN), focusing on its regional revenue contribution. As of April 6, 2025, the company reported significant revenue from the United States (78.10%), followed by Europe (19.31%) and China (2.59%). Details regarding revenue by business …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Simply Wall Street Earnings Main company 🇺🇸 United States

LEGN: Future Returns Expected From Expanding Multiple Myeloma Franchise Execution

Legend Biotech's fair value estimate has been trimmed to $54.23, reflecting cautious assumptions about Carvykti's competitive position and profitability. Analysts are divided, with some highlighting Carvykti's growth and pipeline potential, while others express concerns about intensifying competition and commercial execution in the multiple myeloma …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Earnings Main company 🇺🇸 United States

Legend Biotech Shares Fall After UBS Downgrade

Legend Biotech (LEGN) shares dropped following a downgrade from UBS, which cited increased competition and potential pricing pressure for its CAR-T therapy, Carvykti. Despite Carvykti's strong performance, recent positive developments from competitors like Arcellx and KarXT for competitive blood cancer treatments have led UBS …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Analyst action Main company 🇺🇸 United States

UBS downgrades Legend Biotech stock rating on competition concerns

UBS has downgraded Legend Biotech Corp. (NASDAQ:LEGN) to Neutral from Buy and reduced its price target due to increasing competition in the Multiple Myeloma market. The firm highlighted new clinical benchmarks set by Johnson & Johnson's products and anticipated significant traction for Gilead's anito-cel, …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GuruFocus Analyst action Main company 🇺🇸 United States

LEGN Downgraded by UBS -- Price Target Lowered to $28

UBS has downgraded Legend Biotech (LEGN) to 'Neutral' and lowered its price target from $49.00 to $28.00, reflecting a significant shift in analyst sentiment. Despite a GF Value™ indicating that LEGN is 76.6% undervalued, the high P/E ratio and recent insider selling suggest caution …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Ad-hoc-news.de Earnings Main company 🇺🇸 United States

LEGN stock holds after Legend Biotech reports 2025 revenue growth

Legend Biotech reported significant revenue growth in 2025, reaching $750.6 million, a 68.7% increase year-over-year, primarily driven by its CAR-T therapy, CARVYKTI. Despite a net loss of $64.0 million from continuing operations, the company holds a strong cash position of $1.7 billion, allowing it …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Benzinga Earnings Main company 🇺🇸 United States

Top 3 Health Care Stocks That May Rocket Higher In July

This article identifies three oversold healthcare stocks—Legend Biotech Corp (LEGN), Opus Genetics Inc (IRD), and Anbio Biotechnology (NNNN)—that may present buying opportunities in July. The analysis is based on their Relative Strength Index (RSI) being near or below 30, indicating deeply oversold conditions. Each …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Analyst action Main company 🇺🇸 United States

H.C. Wainwright reiterates Legend Biotech stock rating on strong Carvykti sales

H.C. Wainwright reiterated a Buy rating and a $65.00 price target for Legend Biotech Corp. following strong Carvykti sales of $657 million in Q2 2026. The company is experiencing robust revenue growth and analysts predict profitability this year, despite recent stock declines caused by …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quiver Quantitative Market update Main company 🇺🇸 United States

Lobbying Update: $90,000 of LEGEND BIOTECH CORPORATION lobbying was just disclosed

LEGEND BIOTECH CORPORATION (LEGN) disclosed $90,000 in lobbying expenses for Q2 2026, focusing on educating Congress about biotechnology's role in healthcare. Insider trading data shows two sales by the CEO, totaling $169,404, while hedge funds exhibit mixed activity with significant additions and removals of …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Legend Biotech (NASDAQ: LEGN) reports $657M CARVYKTI sales

Legend Biotech (NASDAQ: LEGN) reported preliminary net trade sales of approximately $657 million for CARVYKTI® for the quarter ended June 30, 2026, based on data provided by Janssen. This figure has not been independently verified or audited by Legend Biotech's accountants and is subject …

LEGN main company
Sharemaestro market context Price below Trend Line 52 weeks -42.7% LEGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context